Tumor Necrosis Factor Inhibitors - Abstract - Europe PMC Sign in | Create an account https://orcid.org
Europe PMC Menu About Tools Developers Help Contact us Helpdesk Feedback Twitter Blog …

During the past 30 years, elucidation of the pathogenesis of rheumatoid arthritis, Crohn's
disease, psoriasis, psoriatic arthritis and ankylosing spondylitis at the cellular and molecular …

In 1975 tumor necrosis factor (TNF) was defined as an endotoxin-induced serum factor
which produced necrosis of tumors both in vitro and in vivo. 1 The original works on TNF …

Tumor necrosis factor (TNF) plays a crucial role in the pathogenesis of immune-mediated
inflammatory diseases (IMID). As a result, the inhibition of TNF is an important therapeutic …

Tumour necrosis factor-alpha (TNF-α) is a proinflammatory cytokine that has been
implicated in the pathogenesis of a spectrum of medical disorders. Mononuclear cells that …

Clinical pharmacokinetics of the 3 existing marketed tumor necrosis factor (TNF)
antagonists, adalimumab (Abbott Laboratories), etanercept (Amgen, Inc.), and infliximab …

TNF-α is a crucial pro-inflammatory and immunregulatory cytokine that is central to the
pathogenesis of various inflammatory and autoimmune conditions. A number of controlled …

The cytokine, tumour necrosis factor‐alpha (TNF‐α) plays a key role in the pathogenesis of
many chronic inflammatory and rheumatic diseases, in particular, Crohn's disease …

In 1998 we wrote an editorial concerning tumor necrosis factor-α (TNF-α) inhibitors as 2 of
them, etanercept and infliximab, were about to be introduced into the clinic1. At that time …

Tumor necrosis factor (TNF) was first identified in 1984 as a cytokine with anti-tumor effects
in vitro and in vivo. Extensive research since then has shown that there are at least 18 …